6533b82cfe1ef96bd128f797
RESEARCH PRODUCT
What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort
Emilie BarbierPhilippe RonchinAstrid LièvreManon BacciNabil Baba-hamedLaurène ParrotLaurent QueroP. PommierLucas SpindlerCôme LepageLaurent SiproudhisVéronique VendrelyL. BazireClaire LemanskiEric FrancoisEleonor Rivin Del CampoLaurent AbramowitzFrédéric JuguetIsabelle Etienneysubject
Malemedicine.medical_specialtyLocal excisionLocal excisionmedicine.medical_treatmentAnal Canal[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineAgedRetrospective StudiesAged 80 and overUnivariate analysisHepatologyRadiotherapybusiness.industryOptimal treatmentGastroenterologyAnal Squamous Cell CarcinomaChemoradiotherapyMiddle AgedAnusAnus Neoplasms3. Good healthRadiation therapymedicine.anatomical_structureAnal canal carcinoma030220 oncology & carcinogenesisCohortCarcinoma Squamous CellFemaleFrancebusinessChemoradiotherapydescription
International audience; Introduction: for localized T1N0 squamous cell carcinoma of the anus (SCCA) standard radiotherapy (RT) may result in overtreatment and alternative strategies are debated. Methods: T1N0M0 SCCA treated between 2015 and 2020 by local excision (LE) or RT were analyzed from the French prospective FFCD ANABASE cohort. Treatment strategies, recurrence-free and colostomy-free survivals (RFS, CFS) and prognostic factors were reported. Results: among 1135 SCCA patients, 99 T1N0M0 were treated by LE(n = 17,17.2%), or RT ( n = 82,82.8%) including RT alone ( n = 65,79.2%) or chemo-RT ( n = 17, 20.7%). Median follow-up was 27.2 months [0.03 and ndash;54.44]. Median tumor size were 11.4 mm [0.9 and ndash;20] and 15.3 mm [2 and ndash;20] in the LE and RT groups respectively. Mean RT tumor dose was 59.4 Gy [18 and ndash;69.4 Gy]. One patient in LE group and 9 in RT group had a pelvic recurrence, either local (60%), nodal (10%) or both (30%). RFS and CFS at 24 months were 92.2%[95%CI,83.4 and ndash;96.4] and 94.6%[95%CI,86.1 and ndash;98.0], at 36 months 88.1%[95%CI,77.1 and ndash; 94.2] and 88.5%[95%CI,77.0 and ndash;94.5], in LE and RT group respectively, without any significative difference (HR = 0.57;[95%CI,0.07 and ndash;4.45];p= 0.60). By univariate analysis, male gender was the only prognostic fac-tor(HR = 5.57;95%CI, 1.76 and ndash;17.63; p = 0.004). Conclusion: this cohort confirms the heterogeneity of T1N0M0 SCCA management, questioning the place of RT alone, reduced dose or RT volume, and the safety of LE. (c) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
year | journal | country | edition | language |
---|---|---|---|---|
2021-06-01 |